Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Taisho, Takeda Each Market OTC Anti-Smoking Patches In Japan

This article was originally published in PharmAsia News

Executive Summary

Taisho Pharmaceutical plans to sell an anti-smoking patch in Japan ahead of Takeda Pharmaceutical's own plans to sell a similar treatment for nicotine addiction. Taisho, which codeveloped Ciganon CQ with the U.K.'s GlaxoSmithKline, said it plans to take advantage of the Health Ministry's recent lifting of a ban on such over-the-counter drugs. Takeda said it would market Johnson & Johnson's Nicorette Patch, but both treatments follow the first on the market, Novartis Pharma's Nicotinell, which began selling May 31, just after the ministry eased its regulation. (Click here for more

Table

View full table

Tags:
Latest Headlines

‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma

Executives On The Move: Three New CEOs Among This Week's Changes

Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

See All
UsernamePublicRestriction

Register

SC068746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By